10 Best Small-Cap Growth Stocks to Buy Now

3. Sage Therapeutics, Inc. (NASDAQ:SAGE)

3-Year Sales Growth: 86.99%

Number of Hedge Fund Holders: 27

Sage Therapeutics, Inc. (NASDAQ:SAGE) is a biopharmaceutical company specializing in developing solutions for brain health disorders. Its key products include ZURZUVAE, which is a neuroactive steroid acting as a positive allosteric modulator of GABA receptors, targeting both synaptic and extrasynaptic GABA receptors. The company has a robust pipeline including SAGE-324, a novel GABA receptor-positive allosteric modulator intended for chronic oral dosing, and other compounds like SAGE-319, SAGE-039, and SAGE-817.

In 2024, Sage Therapeutics, Inc. (NASDAQ:SAGE) experienced significant success with the early commercialization of ZURZUVAE as the drug was marked as the first oral treatment approved for adults with postpartum depression (PPD). During the fiscal fourth quarter of 2024, nearly 2,500 prescriptions of ZURZUVAE were shipped, marking a 21% increase from the third quarter despite fewer days in the field due to the holiday season. Moreover, across the full year, more than 6,600 prescriptions were shipped, indicating strong demand growth.

Looking ahead, Sage Therapeutics, Inc. (NASDAQ:SAGE) plans to invest in a joint sales force expansion to cover more healthcare providers. It also plans to invest in media opportunities to amplify the message that PPD is an urgent medical condition and increase awareness through social media and direct-to-consumer efforts, including potential branded TV media. It is one of the best small-cap growth stocks to buy now.